Silvia Vázquez
Research Subjects
Silvia Vázquez has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Adela Rodriguez-Hernandez
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
10 shared publications - Aleix Prat
Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain
10 shared publications - Ana Vivancos
Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
10 shared publications - Benedetta Conte
Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
10 shared publications - Cristina Hernando
Biomedical Research Institute INCLIVA, Valencia, Spain
10 shared publications - Elia Seguí
Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB) 1 , Barcelona, Spain
10 shared publications
Latest Publications
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S9-S17 showing mutivariate and bivariate analysis for ORR, CBR, PFS and OS
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 9-17 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S9-S17 showing mutivariate and bivariate analysis for ORR, CBR, PFS and OS
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Patient-level raw gene expression data of FFPE tumor samples and best overall response rate
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Patient-level raw gene expression data of FFPE tumor samples and best overall response rate
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Data from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose:Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting.Patients and Methods:The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly).Results:The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit.Conclusions:These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose:Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting.Patients and Methods:The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly).Results:The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit.Conclusions:These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
- Open Access
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 5-8 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S5-8 showing results from univariate analysis for ORR, CBR, PFS and OS
- 1 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 5-8 from Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Tables S5-8 showing results from univariate analysis for ORR, CBR, PFS and OS
- Open Access
- 22 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (7) , 1246-1257
Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose: Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting. Patients and Methods: The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly). Results: The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit. Conclusions: These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.
- 22 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (7) , 1246-1257
Open AccessPembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Purpose: Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting. Patients and Methods: The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly). Results: The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit. Conclusions: These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.